Vertex Pharmaceuticals (VRTX) EPS & PE Ratio History
Current and historical earning per share (EPS) and price to earnings (PE) ratio for Vertex Pharmaceuticals (VRTX) over the last 10 years. The current PE ratio for Vertex Pharmaceuticals as of October 20, 2017 is 572.70.
|Medical||Medical - Biomedical and Genetics||$38.985B||$1.702B|
|Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)|